Literature DB >> 16278384

Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas.

Colleen M Feltmate1, Kenneth R Lee, Michael Johnson, John O Schorge, Kwong-Kwok Wong, Ke Hao, William R Welch, Debra A Bell, Ross S Berkowitz, Samuel C Mok.   

Abstract

PURPOSE: Mucinous adenocarcinoma of the ovary is one of the common histologic types of ovarian cancer. Its pathogenesis is largely unknown. In addition, the differential diagnosis of metastatic mucinous carcinomas to the ovaries, particularly those originating from the appendix, remains challenging. The purpose of this study is to identify molecular biomarkers for mucinous ovarian adenocarcinoma and compare them with those of appendiceal origin. EXPERIMENTAL
DESIGN: Genome-wide loss-of-heterozygosity (LOH) analysis was done on DNA isolated from 28 microdissected primary mucinous ovarian carcinomas and five appendiceal adenocarcinomas. Markers from high-loss regions were selected for further analysis on a total of 32 ovarian and 14 appendiceal cancers.
RESULTS: High levels of LOH rates (>40%) were detected on chromosome arms 9p, 17p, and 21q in mucinous ovarian carcinoma cases. The frequency of allelic loss was similar between high-grade and low-grade mucinous ovarian carcinoma cases but was significantly higher in ovarian versus appendiceal cases. In addition, LOH rates on five chromosomal loci were statistically different between ovarian and appendiceal carcinomas.
CONCLUSION: A high frequency of LOH can be found in mucinous ovarian adenocarcinomas independent of grade. Despite histologic similarities between mucinous ovarian carcinomas and metastatic appendiceal carcinomas, they have distinct LOH profiles, which may be used for distinguishing the two diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278384     DOI: 10.1158/1078-0432.CCR-05-1008

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Authors:  Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2013-12-14       Impact factor: 5.482

Review 2.  Large-scale genomic analysis of ovarian carcinomas.

Authors:  Kylie L Gorringe; Ian G Campbell
Journal:  Mol Oncol       Date:  2008-12-24       Impact factor: 6.603

3.  A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Authors:  V A Heinzelmann-Schwarz; M Gardiner-Garden; S M Henshall; J P Scurry; R A Scolyer; A N Smith; A Bali; P Vanden Bergh; S Baron-Hay; C Scott; D Fink; N F Hacker; R L Sutherland; P M O'Brien
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

4.  Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Authors:  Robertson Mackenzie; Stefan Kommoss; Boris J Winterhoff; Benjamin R Kipp; Joaquin J Garcia; Jesse Voss; Kevin Halling; Anthony Karnezis; Janine Senz; Winnie Yang; Elena-Sophie Prigge; Miriam Reuschenbach; Magnus Von Knebel Doeberitz; Blake C Gilks; David G Huntsman; Jamie Bakkum-Gamez; Jessica N McAlpine; Michael S Anglesio
Journal:  BMC Cancer       Date:  2015-05-19       Impact factor: 4.430

5.  Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables.

Authors:  Xiao Guan; Ning Zhang; Yongshuo Yin; Beihua Kong; Qifeng Yang; Zhiyan Han; Xingsheng Yang
Journal:  J Exp Clin Cancer Res       Date:  2012-10-24

6.  Histotype-specific copy-number alterations in ovarian cancer.

Authors:  Ruby Yunju Huang; Geng Bo Chen; Noriomi Matsumura; Hung-Cheng Lai; Seiichi Mori; Jingjing Li; Meng Kang Wong; Ikuo Konishi; Jean-Paul Thiery; Liang Goh
Journal:  BMC Med Genomics       Date:  2012-10-18       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.